Full Year 2023 Investor Presentation

44 Investor presentation Full year 2023 Novo Nordisk has 55% of the global GLP-1 market, while GLP-1 penetration of diabetes volume varies across regions 80% 60% 40% 20% GLP-1 market growth and Novo Nordisk market share Novo NordiskⓇ GLP-1 share of total estimated diabetes prescriptions¹ is 6% Million prescriptions¹ 250 53% 200 53% Global: 2% 55% 150 55% 100 50 0% 0 Nov Nov 2018 2020 2023 -NN market share NN share of growth GLP-1 -Market growth Source: IQVIA MAT value (spot rate), Nov 2023; Market values are based on the list prices NN growth SGLT-2i DPP-4i Insulin Global: 6% 2023 Trad. OAD GLP-1 share of estimated diabetes prescriptions 1 The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full- year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions Source: IQVIA MAT volume (Spot rate), Nov 2023; Market values are based on the list prices

View entire presentation